{
    "nctId": "NCT01006785",
    "briefTitle": "Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer",
    "officialTitle": "Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Best overall response rate: proportion of subjects with either complete or partial response according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria at the end of study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects diagnosed with Stage IIIB or IV breast cancer who have failed with or refuse to receive standard chemotherapies\n* Subjects with the expression of ER/PR negative; or positive ER/PR expression but have failed with or refuse to receive hormonal therapy\n* Either + or - expression of HER-2/neu gene\n* ECOG status = 0-2\n* At least have 1 evaluable and measurable metastatic lesion as defined by RECIST criteria\n* Adequate haematological, liver, and renal function\n* At least 3 weeks has elapsed since prior chemotherapy, radiotherapy, biological/hormonal therapy\n* At least 4 weeks has elapsed since surgical biopsy / major surgery\n\nExclusion Criteria:\n\n* Allergic to the trial product\n* Any other disease state, including infections or uncontrolled illnesses that could interfere with trial participation or trial evaluation\n* Concurrent herbal (alternative) medicine or food supplements suspected to have effect on cancer disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}